Kymera Therapeutics

formerly KymeraIPO

Revolutionary Medicines Catalyzed by Protein Degradation

Public · Boston, United States · Founded 2016 · $167.0M raised

Employees
51–200
Founded
2016
Business Model
Other
Total Funding
$167.0M
Last Round
$102.0M Series CMar 2020
Rounds
2
Type
Public

About

Kymera Therapeutics is a clinical-stage biotechnology company pioneering targeted protein degradation to develop oral small molecule medicines addressing critical health problems in immunology and oncology. Its proprietary platform enables degradation of disease-causing proteins, transforming treatment paradigms for undruggable targets.

Summary

Kymera Therapeutics is a Biotech company based in Boston, United States, founded in 2016. It has raised $167.0M in total across 2 rounds, most recently a $102.0M Series C round in Mar 2020. Investors include Biotechnology Value Fund, Redmile Group and Bain Capital.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

IPODec 2025
$602.0M

Sign up to see all 5 rounds

Series B through IPO — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Kymera Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/kymera-therapeutics"><img src="https://indexed.vc/api/badge/company/kymera-therapeutics" alt="Kymera Therapeutics on Indexed.vc" width="260" height="76" /></a>